Abstract:Background: The European (EU) genotype of porcine reproductive and respiratory syndrome virus (Genotype-I PRRSV) has recently emerged in China. The coexistence of Genotype-I and -II PRRSV strains could cause seriously affect PRRSV diagnosis and management. Current vaccines are not able to protect against PRRSV infection completely and have inherent drawbacks. Thus, genetically engineered vaccines, including DNA vaccine and live vector engineered vaccines, have been developed. This study aimed to determine the enhanced immune responses of mice inoculated with a DNA vaccine coexpressing GP3 and GP5 of a Genotype-I PRRSV. Results: To evaluate the immunogenicity of GP3 and GP5 proteins from European-type PRRSV, three DNA vaccines, pVAX1-EU-ORF3-ORF5, pVAX1-EU-ORF3 and pVAX1-EU-ORF5, were constructed, which were based on a Genotype-I LV strain (GenBank ID: M96262). BALB/c mice were immunized with the DNA vaccines; delivered in the form of chitosan-DNA nanoparticles. To increase the efficiency of the vaccine, Quil A (Quillaja) was used as an adjuvant. GP3 and GP5-specific antibodies, neutralizing antibodies and cytokines (IL-2, IL-4, IL-10 and IFN gamma) from the immunized mice sera, and other immune parameters, were examined, including T-cell proliferation responses and subgroups of spleen T-lymphocytes. The results showed that ORF3 and ORF5 proteins of Genotype-I PRRSV induced GP3 and GP5-specific antibodies that could neutralize the virus. The levels of Cytokines IL-2, IL-4, IL-10, and IFN-γ of the experimental groups were significantly higher than those of control groups after booster vaccination (P < 0.05). The production of CD3+CD4+ and CD3+CD8+ T lymphocyte was also induced. T lymphocyte proliferation assays showed that the PRRSV LV strain virus could stimulate the proliferation of T lymphocytes in mice in the experimental group. Conclusions: Using Quil A as adjuvant, Genotype-I PRRSV GP3 and GP5 proteins produced good immunogenicity and reactivity. More importantly, better PRRSV-specific neutralizing antibody titers and cell-mediated immune responses were observed in mice immunized with the DNA vaccine co-expressing GP3 and GP5 proteins than in mice immunized with a DNA vaccine expressing either protein singly. The results of this study demonstrated that co-immunization with GP3 and GP5 produced a better immune response in mice.

Construction and Immunogenicity of DNA Vaccines Encoding Fusion Protein of Porcine IFN- Λ 1 and GP5 Gene of Porcine Reproductive and Respiratory Syndrome Virus.

Construction and immunogenicity of a DNA vaccine coexpressing GP3 and GP5 of genotype-I porcine reproductive and respiratory syndrome virus

Assessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus

Porcine GPX1 enhances GP5-based DNA vaccination against porcine reproductive and respiratory syndrome virus

Immunogenicity of the highly pathogenic porcine reproductive and respiratory syndrome virus GP5 protein encoded by a synthetic ORF5 gene

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo

DNA vaccines co-expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus (PRRSV) display enhanced immunogenicity.

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines <i>in vivo</i>

Highly Efficient Expression of Interleukin-2 under the Control of Rabbit Beta-Globin Intron Ii Gene Enhances Protective Immune Responses of Porcine Reproductive and Respiratory Syndrome (prrs) Dna Vaccine in Pigs

Enhanced immunogenicity of the modified GP5 of porcine reproductive and respiratory syndrome virus

Study on Immunological Responses to Porcine Reproductive and Respiratory Syndrome Virus DNA Vaccines Co-expressing Modified GP5 (gp5m) and M Proteins

Enhancing immunogenicity and antiviral protection of inactivated porcine reproductive and respiratory syndrome virus vaccine in piglets

Evaluation of a DNA Vaccine Candidate Co-Expressing GP3 and GP5 of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) with Interferon Α/γ in Immediate and Long-Lasting Protection Against HP-PRRSV Challenge

Adsorption of a Porcine Reproductive and Respiratory Syndrome Virus DNA Vaccine Candidate Onto Biodegradable Nanoparticles Improves Immunogenicity in Mice

Immunization in Pigs Vaccined with DNA Encoding PRRSV GP5

[Eukaryotic expression of GP5 and M protein of porcine reproductive and respiratory syndrome virus and immunogenicity evaluation]

Positive inductive effect of IL-18 on virus-specific immune responses induced by PRRSV-GP5 DNA vaccine in swine

Construction and Immunogenicity of Recombinant Expression Vectors for GP5 and M Proteins of Porcine Reproductive and Respiratory Syndrome Virus

[Immunogenicity of DNA Vaccine Expressing GP5 of Porcine Reproductive and Respiratory Syndrome Virus Fused with VP22 of Bovine Herpesvirus 1].

Immune Responses in Pigs Induced by Recombinant DNA Vaccine Co-Expressing Swine IL-18 and Membrane Protein of Porcine Reproductive and Respiratory Syndrome Virus.

Enhanced Humoral Immune Response of DNA Vaccine Composing a Modified ORF5 Gene of Porcine Reproductive and Respiratory Syndrome Virus